Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1

Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1

Abstract Background Immune checkpoint blockade (ICB) therapy has demonstrated considerable clinical benefit in several malignancies, but has shown favorable response in only a small proportion of cancer patients. Recent studies have shown that matrix metalloproteinases (MMPs) are highly associated w...

Full description

Bibliographic Details
Main Authors: Youqiong Ye, Xinwei Kuang, Zuozhong Xie, Long Liang, Zhao Zhang, Yongchang Zhang, Fangyu Ma, Qian Gao, Ruimin Chang, Heng-Huan Lee, Shuang Zhao, Juan Su, Hui Li, Jingbo Peng, Huifang Chen, Minzhu Yin, Cong Peng, Nong Yang, Jing Wang, Jing Liu, Hong Liu, Leng Han, Xiang Chen
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Genome Medicine
Subjects:
Immune checkpoint blockade
Matrix metalloproteinases (MMPs)
SB-3CT
Combination treatment
Online Access:http://link.springer.com/article/10.1186/s13073-020-00780-z

Internet

http://link.springer.com/article/10.1186/s13073-020-00780-z

Similar Items